sequential testing. As a result, he published papers
in Biometrika and Statistics and Probability Letters Further Reading
(see “Further Reading”). He also contributed to the
Chang, M.N, Gould A.L., and Snapinn S.M. (1995). “P-Values for
development of a burden of illness method combin-
Group Sequential Testing.” Biometrika, 82(3):650–654.
ing incidence and severity of disease for a vaccine
Chang, M.N, Guess, H.A., and Heyse, J.H. (1994). “Reduction in
clinical trial for herpes zoster, which resulted in a
Burden of Illness: A New Efficacy Measure for Prevention Trials.”
paper published in Statistics in Medicine.
Statistics in Medicine, 13:1807–1814.
Heitjan, currently at the University of
Heiberger, R.M. and Holland, B. (2004). Statistical Analysis and Data
Pennsylvania, was another active scholar. He
Display: An Intermediate Course with Examples in S-Plus, R, and
taught courses on longitudinal analysis with miss-
SAS. New York: Springer-Verlag.
ing data and provided consultation on longitudinal
Heiberger, R.M. and Neuwirth, E. (2009). R Through Excel: A
trials and missing data. His primary collaboration
Spreadsheet Interface for Statistics, Data Analysis, and Graphics.
was on a program involved with analyzing intra-
New York: Springer-Verlag.
ocular pressure data from glaucoma clinical trials
Heitjan, D.F. and Sharma D. (1997). “Modeling Repeated-Series
using repeated-series longitudinal models, which led
Longitudinal Data.” Statistics in Medicine, 16:347–355.
to a 1997 publication in Statistics in Medicine. He
also worked on causal models with noncompliance
Heitjan, D.F. (1999A). “Causal Inference in a Clinical Trial: A Com-
and published papers about his work in Controlled
parative Example.” Controlled Clinical Trials, 20:309–318.
Clinical Trials and Statistics in Medicine.
Heitjan D.F. (1999B). “Ignorability and Bias in Clinical Trials.”
Stine’s (University of Pennsylvania) experiences
Statistics in Medicine, 18:2421–2434.
as a Schor scholar were similar, but with different
Amit, O., Heiberger, R.M., and Lane, P.W. (2008) “Graphical
areas of emphasis. He worked on a prediction model
Approaches to the Analysis of Safety Data from Clinical Trials.”
of osteoporosis that led to statistical methods for
Pharmaceutical Statistics, 7(1):20–35.
measuring overlap in distributions, which he wrote
Oxman M.N., Levin, M.J., Johnson, G.R., et al. (2005). “A Vac-
about in a 2001 Statistics in Medicine article. Stine’s
cine to Prevent Herpes Zoster and Postherpetic Neuralgia in
consulting and teaching was primarily in preclini-
Older Adults.” The New England Journal of Medicine, 352:2271–
cal animal studies of blood pressure in a longitudi-
2284.
nal setting, and he used his background in business
Shih, W.J., Quan, H., and Chang, M.N. (1994). “Estimation of
statistics to help the marketing department with a
the Mean When Data Contain Non-Ignorable Missing Values
promotion-response study using a mixture model
from a Random Effects Model.” Statistics and Probability Letters,
with excess zeros.
19:249–257.
Richard M. Heiberger, a statistics professor
Stine, R.A. and Heyse, J.F. (2001). “Non-Parametric Estimates of
at Temple University, took a sabbatical at GSK’s
Overlap.” Statistics in Medicine, 20:215–236.
Research Statistics Unit during the 2003–2004
academic year. He participated in a company-wide
investigation into the use of graphics in clinical trial
reports and submissions, culminating in a paper
interfaces, which allow clinical staff direct access to
published in Pharmaceutical Statistics. He also gave
the underlying simulation software written in R.
seminars and taught two short courses based on
There are at least two journal articles in preparation
his book Statistical Analysis and Data Display: An
based on this work.
Intermediate Course with Examples in S-Plus, R, and
These experiences illustrate that important
SAS. Beginning in January 2009, Heiberger entered
problems in pharmaceutical statistics have been
into a research contract with GSK through Temple
addressed by developing, applying, and publishing
University for a one-day-a-week collaboration. He
novel statistical methods in actual drug and vaccine
began his current collaboration with a seminar on
research settings. These programs provide academic
the RExcel interface, which is the topic of his new
statisticians experience in solving real-world indus-
book, R Through Excel: A Spreadsheet Interface for
trial problems, while allowing industry statisticians
Statistics, Data Analysis, and Graphics.
to maintain their theoretical foundation. They also
Heiberger has built upon the experience he
can lead to long-term relationships between aca-
gained in the design of clinical trials simula-
demia and industry. n
tion experiments by designing Excel-based user
OCTObER 2009 AMsTAT NEWs 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100